Anavex Life Sciences Corp
AVXL
NASDAQ
Biotechnology
$3.22
USD
-0.05 (-1.53%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $300.34M
Volume 698.1K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-39.95M
TTM
+14.1%
YoY
Operating Cash Flow
$-34.08M
TTM
+4.3%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 3.1 | 2.6 | 4.5 | 3.6 | 2.1 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 13.6 | 12.5 | 14.5 | 10.8 | 6.8 |
Operating Income | -13.6 | -12.5 | -14.5 | -10.8 | -6.8 |
EBITDA | -13.6 | -12.5 | -14.5 | -10.8 | -6.8 |
Other Income / Expense | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 |
Total Other Income / Expense | 1.5 | 1.3 | 1.2 | 1.0 | 1.1 |
Income Before Income Taxes | -12.1 | -11.2 | -13.2 | -9.8 | -5.7 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -12.1 | -11.2 | -13.2 | -9.8 | -5.7 |
Consolidated Net Income / Loss | -12.1 | -11.2 | -13.2 | -9.8 | -5.7 |
Net Income Attributable to Common Shareholders | -12.1 | -11.2 | -13.2 | -9.8 | -5.7 |
Basic EPS | -$0.14 | -$0.13 | -$0.16 | -$0.11 | -$0.06 |
Diluted EPS | -$0.14 | -$0.13 | -$0.16 | -$0.11 | -$0.06 |
Basic Shares Outstanding | 84.8M | 85.1M | 85.4M | 85.9M | 89.0M |
Diluted Shares Outstanding | 84.8M | 85.1M | 85.4M | 85.9M | 89.0M |